164 related articles for article (PubMed ID: 1320915)
1. Are all 5-HT3 receptor antagonists the same?
Andrews PL; Bhandari P; Davey PT; Bingham S; Marr HE; Blower PR
Eur J Cancer; 1992; 28A Suppl 1():S2-6. PubMed ID: 1320915
[TBL] [Abstract][Full Text] [Related]
2. Are granisetron and ondansetron equivalent in the clinic?
Dilly S
Eur J Cancer; 1992; 28A Suppl 1():S32-5. PubMed ID: 1320918
[TBL] [Abstract][Full Text] [Related]
3. RG 12915: a potent 5-hydroxytryptamine-3 antagonist that is an orally effective inhibitor of cytotoxic drug-induced emesis in the ferret and dog.
Fitzpatrick LR; Lambert RM; Pendley CE; Martin GE; Bostwick JS; Gessner GW; Airey JE; Youssefyeh RD; Pendleton RG; Decktor DL
J Pharmacol Exp Ther; 1990 Aug; 254(2):450-5. PubMed ID: 2166791
[TBL] [Abstract][Full Text] [Related]
4. Review of experience with ondansetron and granisetron.
Aapro MS
Ann Oncol; 1993; 4 Suppl 3():9-14. PubMed ID: 8395875
[TBL] [Abstract][Full Text] [Related]
5. 5-HT3 receptor antagonists, a new approach in emesis: a review of ondansetron, granisetron and tropisetron.
Seynaeve C; Verweij J; de Mulder PH
Anticancer Drugs; 1991 Aug; 2(4):343-55. PubMed ID: 1665723
[TBL] [Abstract][Full Text] [Related]
6. Development of high-affinity 5-HT3 receptor antagonists. 1. Initial structure-activity relationship of novel benzamides.
Youssefyeh RD; Campbell HF; Klein S; Airey JE; Darkes P; Powers M; Schnapper M; Neuenschwander K; Fitzpatrick LR; Pendley CE
J Med Chem; 1992 Mar; 35(5):895-903. PubMed ID: 1312602
[TBL] [Abstract][Full Text] [Related]
7. The effects of orally administered Y-25130, a selective serotonin3-receptor antagonist, on chemotherapeutic agent-induced emesis.
Haga K; Inaba K; Shoji H; Morimoto Y; Fukuda T; Setoguchi M
Jpn J Pharmacol; 1993 Nov; 63(3):377-83. PubMed ID: 8107329
[TBL] [Abstract][Full Text] [Related]
8. Serotonin antagonists: a new class of antiemetic agents.
Hesketh PJ; Gandara DR
J Natl Cancer Inst; 1991 May; 83(9):613-20. PubMed ID: 1850806
[TBL] [Abstract][Full Text] [Related]
9. Antiemetic control: 5-HT3 antagonists: review of clinical results, with particular emphasis on ondansetron.
Kidgell AE; Butcher ME; Brown GW
Cancer Treat Rev; 1990 Sep; 17(2-3):311-7. PubMed ID: 2176933
[No Abstract] [Full Text] [Related]
10. DAT-582, a novel serotonin3 receptor antagonist, is a potent and long-lasting antiemetic agent in the ferret and dog.
Yoshida N; Omoya H; Ito T
J Pharmacol Exp Ther; 1992 Mar; 260(3):1159-65. PubMed ID: 1532032
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial of two doses of granisetron in the treatment of chemotherapy-induced emesis. Dutch results within a multinational study.
Bots MW; Dijkstra HJ; Blijham GH; van der Wall E; Fehmers MC; Keizer HJ; Nortier JW; Siegenbeek van Heukelom L; Slee PH; Veenhof CH
Neth J Med; 1992 Jun; 40(5-6):221-6. PubMed ID: 1331830
[TBL] [Abstract][Full Text] [Related]
12. Are there differences among the serotonin antagonists?
Tonato M; Roila F; Del Favero A
Support Care Cancer; 1994 Sep; 2(5):293-6. PubMed ID: 8000725
[TBL] [Abstract][Full Text] [Related]
13. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
Slabý J; Trnený M; Procházka B; Klener P
Neoplasma; 2000; 47(5):319-22. PubMed ID: 11130251
[TBL] [Abstract][Full Text] [Related]
14. 5-hydroxytryptamine-3 antagonists: a new class of potent antiemetics in cancer therapy.
Soukop M
Recent Results Cancer Res; 1991; 121():86-90. PubMed ID: 1650016
[No Abstract] [Full Text] [Related]
15. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
[TBL] [Abstract][Full Text] [Related]
16. The budgetary impact of 5-HT3 receptor antagonists in the management of chemotherapy-induced emesis.
Jones AL; Lee GJ; Bosanquet N
Eur J Cancer; 1992; 29A(1):51-6. PubMed ID: 1332738
[TBL] [Abstract][Full Text] [Related]
17. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
Gregory RE; Ettinger DS
Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240
[TBL] [Abstract][Full Text] [Related]
18. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy--a randomised study.
Jantunen IT; Muhonen TT; Kataja VV; Flander MK; Teerenhovi L
Eur J Cancer; 1993; 29A(12):1669-72. PubMed ID: 8398291
[TBL] [Abstract][Full Text] [Related]
19. [Recent improvements in antiemetic therapy].
Roila F; Palladino MA; Ciccarese G; Basurto C
Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
[TBL] [Abstract][Full Text] [Related]
20. Antiemetic activity of ondansetron in cancer patients receiving non-cisplatin chemotherapy.
Fraschini G
Semin Oncol; 1992 Aug; 19(4 Suppl 10):41-7. PubMed ID: 1387249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
